Stock Movers
Stock Movers

Sep 29, 2026 · 7 min

Policy shift puts FICO’s credit-score dominance at risk

Piper Sandler Drops, Summit Therapeutics Jumps, Fair Isaac Sinks as New Policy Seen Spurring Competition

The episode links three sharp stock moves to a possible investment-bank combination, a major biotech deal, and rising competition in credit scoring.

3 key takeaways
  1. 1Piper Sandler shares fall as the firm explores a possible combination with Perella Weinberg Partners.
  2. 2Summit Therapeutics rallies after AstraZeneca commits $2 billion to collaborate on its cancer drug candidate ivonescimab.
  3. 3Fair Isaac plunges as a policy proposal could make VantageScore easier for lenders to adopt.

Don't miss

Fair Isaac shares plunge after a policy proposal could make it easier for lenders to adopt VantageScore.

The brief

Piper Sandler shares decline as the firm discusses a possible combination with Perella Weinberg Partners, whose M&A capabilities could complement Piper Sandler’s business.

Summit Therapeutics moves sharply higher after AstraZeneca agrees to invest $2 billion and collaborate on ivonescimab, its cancer drug candidate.

The episode’s clearest market tension arrives with Fair Isaac: a policy proposal could make VantageScore easier for lenders to use, intensifying competition for FICO.

Together, the moves show how corporate deal talks, pharmaceutical investment, and regulatory changes can quickly reshape expectations for individual companies.

What was said on this episode

2 statements · 2 positive

  1. Paul Lejuezon Piper Sandler–Perella Weinberg combinationPositive1:26

    Perella Weinberg’s M&A advisors would complement Piper Sandler’s capabilities.

    “I think this For Sandler, I think this would be a great deal because they have some capital markets, some good capital markets capabilities. They have some industry expertise, healthcare for example. But boy, the powerful, uh, M&A advisors at Perella Weinberg I think would be a nice fit.”

    Listen at 1:26

  2. Katie Greifeldon AstraZeneca investment in Summit TherapeuticsPositive2:24

    The AstraZeneca investment is beneficial for Summit Therapeutics.

    “So certainly a good move for Summit Therapeutics.”

    Listen at 2:24

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Listen to the full episode and explore every guest, topic, and moment on PodLume.

What is PodLume?

PodLume turns podcasts into searchable knowledge. AI-decoded transcripts, identified guests and topics, smart highlights, and cross-show search across the world’s best conversations — all in your pocket.

Policy shift puts FICO’s credit-score dominance at risk | PodLume